Skip to main content

Specialty Pharmacy

  • FDA gives second orphan drug designation to Teva's Treanda

    JERUSALEM — The Food and Drug Administration has designated a drug made by Teva Pharmaceutical Industries as an orphan drug, the company said.

    Teva said the drug, Treanda (bendamustine hydrochloride), received the designation for indolent B-cell non-Hodgkins lymphoma through October 2015 that has progressed during or within six months of treatment with a regimen containing Rituxan (rituximab), marketed by Genentech and Biogen Idec. The FDA gives orphan drug designation to treatments for diseases affecting fewer than 200,000 people in the United States.

  • Merck drug approved for preventing fungal infections in immunosuppressed patients

    WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a new tablet form of an antifungal drug made by Merck, the company said Tuesday.

    Merck announced the FDA approval of Noxafil (posaconazole) 100-mg delayed release tablets. The company also markets a 40-mg-per-milliliter oral suspension form of the drug. The new tablet formulation is designed to be taken in two 300-mg doses on the first day, followed by a 300-mg dose once per day.

  • AbbVie campaign focuses on women with HIV

    NORTH CHICAGO, Ill. – Drug maker AbbVie is launching an international awareness campaign focused on women living with HIV, the drug maker said Tuesday.

  • Bayer to buy Norway-based Algeta for $2.4 billion

    OSLO, Norway — German chemical and pharmaceutical giant Bayer plans to buy Norwegian drug maker Algeta for $2.4 billion, Algeta confirmed Tuesday.

    Responding to earlier media reports, the Norway-based maker of cancer drugs said Bayer would acquire it for 336 krone per share, equal to about $55.05. The company's share price increased to 349.40 krone, or $57.21 per share, in late-afternoon trading Tuesday on the Oslo Stock Exchange.

  • Hospira announces investor conference

    LAKE FOREST, Ill. — Generic drug maker Hospira will have its investor conference next week, the company said Tuesday.

    The drug maker, based in the Chicago area, will have the investor day at its headquarters on Dec. 5. Hospira specializes in manufacturing injectable generic drugs, including biosimilars for the European market.

    The event will include slide presentations, and the company will stream it via audio webcast at its investors website, hospirainvestor.com.

     

  • Symphony Health Solutions study predicts 5% rise in statin prescriptions following new cholesterol guidelines

    SAN MATEO, Calif. – The number of patients receiving prescriptions for statins is expected to increase modestly following new cholesterol recommendations from the American College of Cardiology and the American Heart Association, according to a new report.

  • FDA approves J&J's Olysio for hepatitis C

    TITUSVILLE, N.J. — The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

  • First wave of Certified Specialty Pharmacist credential recipients includes four from Diplomat

    FLINT, Mich. — Four pharmacists from Diplomat are among the 49 across the country who have received certification from the Specialty Pharmacy Certification Board, Diplomat said Monday.

    Diplomat said VP clinical services Gary Rice, clinical technology manager Michael Crowe, pharmacy manager Nicole Hubach and clinical manager Ryan Nolan had received the SPCB's Certified Specialty Pharmacist endorsement. The SPCB announced on Nov. 11 the first 49 pharmacists to become CSPs. The tests for the credential were administered in October.

X
This ad will auto-close in 10 seconds